Loading the evidence…
Follow an intervention from preclinical studies to human trials and reported outcomes.
| THERAPY / MECHANISM | INJURY MODELS | STUDIES | REPORTED OUTCOME | Open record |
|---|---|---|---|---|
| Rosiglitazone Peroxisome proliferator-activated receptor gamma agonist | Wound · Ischaemia-reperfusion +4 | 92011–2020 | Failed | |
| Sciatic peripheral nerve block with ropivacaine Sodium channel alpha subunit blocker (BLOCKER) | Wound · Other | 32016–2019 | No trauma translation | |
| Sildenafil Phosphodiesterase 5A inhibitor (INHIBITOR) | Radiation · Other +5 | 102011–2020 | No trauma translation | |
| Simvastatin HMG-CoA reductase inhibitor (INHIBITOR), direct interaction, disease efficacy true. | TBI · Chemical/toxin +7 | 152003–2020 | No trauma translation | |
| Sodium butyrate Drug | Other · Chemical/toxin +1 | 32013–2015 | Not approved | |
| Substance P Hormone | Ischaemia-reperfusion · Wound +1 | 32013–2019 | Not approved | |
| Tauroursodeoxycholic acid (TUDCA) Unknown | Spinal cord injury · Other | 32015–2018 | No trauma translation | |
| Tubastatin A (HDAC6 inhibitor), Aurora Kinase A Inhibitor I, and AAV2-delivered shRNAs against IFT88, Kif2a, HEF1, PLK1, NDE1 and TCHP Other | Other · Haemorrhage/shock | 22018–2019 | Not approved | |
| Ulinastatin (urinary trypsin inhibitor) Biologic | Crush · Ischaemia-reperfusion +4 | 82011–2020 | Not approved | |
| Ursolic acid Nutraceutical | Other · Spinal cord injury +1 | 32017–2020 | Not approved |
Study counts are reported at therapy level and can differ from the number of itemised publications. Outcomes are research classifications, not treatment recommendations.